The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Alcoholic Steatohepatitis Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis Market.

Some of the key takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Alcoholic Steatohepatitis treatment therapies with a considerable amount of success over the years. 
• Non-Alcoholic Steatohepatitis companies working in the treatment market are Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others, are developing therapies for the Non-Alcoholic Steatohepatitis treatment 

• Emerging Non-Alcoholic Steatohepatitis therapies such as – GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others are expected to have a significant impact on the Non-Alcoholic Steatohepatitis market in the coming years.   
• In January 2023, Resmetirom, a liver-directed selective thyroid hormone receptor agonist, was tested in the major Phase III MAESTRO-NASH biopsyclinical trial by Madrigal Pharmaceuticals, Inc. At the NASH-TAG Conference, the new MAESTRO-NASH results are being presented
• In July 2022, To assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of orally administered TERN-501 as monotherapy as well as in combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH), TERN Therapeutics started a Phase IIa multicenter, randomised, double-blind, placebocontrolled clinical study
• In August 2022 An international, multi-center, double-blind, randomised, placebo-controlled study was started by Madrigal Pharmaceuticals with patients who had well-compensated NASH cirrhosis. For the duration of the study and until the required number of Composite Clinical Outcome events are reached, participants will be blindly randomised 3:1 to receive either 80 mg of resmetirom or a matching placebo administered orally once daily in the morning
• In November 2022, TERN-501, a thyroid hormone receptor beta (THR-) agonist being developed for the treatment of NASH, was the subject of a Phase 1 research, according to a statement from Terns Pharmaceuticals, Inc. At The Liver Meeting®, the annual conference of the American Association for the Study of Liver Diseases (AASLD), the findings are being emphasised in a poster session
• In January 2021, The company’s IND for TERN-501, a selective thyroid hormone receptor beta, or THR-, agonist with improved metabolic stability and liver distribution, was approved by the US Food and Drug Administration. These features are meant to increase safety and efficacy in NASH patients
• In October 2019, The US FDA has approved Madrigal Pharmaceuticals’ request for Fast Track designation for the use of resmetirom to treat NASH

Get a Free Sample PDF Report to know more about Non-Alcoholic Steatohepatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/non-alcoholic-steatohepatitis-nash-pipeline-insight

Emerging Non-Alcoholic Steatohepatitis Drugs Under Different Phases of Clinical Development Include:

• GMA-107: Gmax Biopharm
• LBS-009: Lin Biosciences
• VK-1430: Viking Therapeutics
• Resmetirom: Madrigal Pharmaceuticals
• MSDC-0602K: Cirius Therapeutics
• ION224: Ionis Pharmaceuticals
• HU 6: Rivus Pharmaceuticals
• HTD 1801: HighTide Biopharma
• EDP-305: Enanta Pharmaceuticals
• SRT-015: Seal Rock Therapeutics
• AZD 2693: AstraZeneca
• BI 456906: Boehringer Ingelheim
• ORMD-0801: Oramed Pharmaceuticals
• EYP001: ENYO Pharma
• TERN-501: Terns Pharmaceuticals
• Semaglutide: NovoNordisk
• Resmetirom: Madrigal Pharmaceuticals
• Lanifibranor: Inventiva Pharma

Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

• Non-Alcoholic Steatohepatitis Assessment by Product Type
• Non-Alcoholic Steatohepatitis By Stage and Product Type
• Non-Alcoholic Steatohepatitis Assessment by Route of Administration
• Non-Alcoholic Steatohepatitis By Stage and Route of Administration
• Non-Alcoholic Steatohepatitis Assessment by Molecule Type
• Non-Alcoholic Steatohepatitis by Stage and Molecule Type

DelveInsight’s Non-Alcoholic Steatohepatitis Report covers around 5+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Alcoholic Steatohepatitis product details are provided in the report. Download the Non-Alcoholic Steatohepatitis pipeline report to learn more about the emerging Non-Alcoholic Steatohepatitis therapies

Some of the key companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Steatohepatitis are – Madrigal Pharmaceuticals, Inc., Intercept Pharmaceuticals, AstraZeneca, Inventiva Pharma, Cirius Therapeutics, Inc, Galectin Therapeutics Inc., Galmed Research and Development, Ltd., Zydus Therapeutics Inc., Rivus Pharmaceuticals, Inc., 89bio, Inc., Lipocine Inc., HighTide Biopharma Pty Ltd, Akero Therapeutics, Inc, Enyo Pharma, Sagimet Biosciences Inc., CytoDyn, Inc., Terns, Inc., Poxel SA, Enanta Pharmaceuticals, Inc, Kowa Company, Ltd., NorthSea Therapeutics B.V., Merck, NGM Biopharmaceuticals, Inc, Hanmi Pharmaceutical Company Limited, Gilead Sciences, Cascade Pharmaceuticals, Inc, Hepion Pharmaceuticals, Inc., Pfizer, Alnylam Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Future Medicine, Boston Pharmaceuticals, MediciNova, Cellaion, Promethera Therapeutics, Viking Therapeutics, Inc., Novo Nordisk A/S, Eccogene, CohBar, Inc., Aligos Therapeutics, Corcept Therapeutics, Altimmune, Inc., Janssen Pharmaceutical K.K., Enanta Pharmaceuticals, Inc, Arrowhead Pharma, Ionis Pharmaceuticals, Inc., Novo Nordisk A/S, Eli Lilly and Company, Novo Nordisk A/S, Metacrine, Inc., Hepagene (Shanghai) Co., Ltd., TaiwanJ Pharmaceuticals Co., Ltd, Viking Therapeutics, Inc., LG Chem, Redx Pharma, and others.

Non-Alcoholic Steatohepatitis Pipeline Analysis:

The Non-Alcoholic Steatohepatitis pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Steatohepatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis Treatment.
• Non-Alcoholic Steatohepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Alcoholic Steatohepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Steatohepatitis drugs and therapies

Non-Alcoholic Steatohepatitis Pipeline Market Drivers

• Rise in prevalence, emerging treatment therapies of NASH, growing demand for NASH therapeutics are some of the important factors that are fueling the Non-Alcoholic Steatohepatitis Market.

Non-Alcoholic Steatohepatitis Pipeline Market Barriers

• However, lack of analogs, use of combination therapies, reimbursement issues and other factors are creating obstacles in the Non-Alcoholic Steatohepatitis Market growth.

Scope of Non-Alcoholic Steatohepatitis Pipeline Drug Insight    

• Coverage: Global
• Key Non-Alcoholic Steatohepatitis Companies: Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others
• Key Non-Alcoholic Steatohepatitis Therapies: GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others
• Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
• Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers 

Request for Sample PDF Report for Non-Alcoholic Steatohepatitis Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services